[Use of VM-26 as a single agent in the treatment of transitional cell carcinoma of the urinary tract].
Y
Y
Aso
T
T
Ushiyama
K
K
Suzuki
A
A
Tajima
Y
Y
Naide
S
S
Ohshima
O
O
Matsuura
M
M
Fukushima
K
K
Ota
Y
Y
Ono
D000328:Adult; D000368:Aged; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D011034:Podophyllotoxin / Q000031:analogs & derivatives*; D013713:Teniposide / Q000008:administration & dosage / Q000627:therapeutic use*; D014516:Ureteral Neoplasms / Q000188:drug therapy*; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy*
D013713:Teniposide; D011034:Podophyllotoxin